REMARKS

In the Office Action, the Examiner has required Applicants to elect a single species to which the claims shall be restricted. Specifically, Applicants are required to define each of A, R₁-R₉, n, D, z, and m, of the compound of formula I, with a particular species, as necessary to elect a single compound, and to identify claims readable on the elected species.

Applicants hereby elect, without traverse, the compound of Example 1 of the specification, i.e., N-hydroxy-2(R)-[[4-methoxyphenylsulfonyl](3-picolyl)-amino]-3-methylbutanamide hydrochloride. Claims 1-5, and 7-10 are readable on the elected species.

Applicants respectfully request that the remarks made herein be entered and made of record in the file history of the present application. If any issues remain in connection herewith, the Examiner is respectfully invited to telephone the undersigned to discuss the same.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc. 400 Technology Square Cambridge, MA 02139 (617) 871-3027

Date: Feb. 4, 2008

Mei L. Benn

Attorney for Applicants

Reg. No. 45,470